Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (TNON) launched its SImmetry+ titanium 3D-printed lateral screw commercially after completing a limited Alpha launch with physicians. The Alpha launch generated approximately $1.2 million in incremental revenue from late Q4 2025 through Q3 2026. That figure is preliminary and unaudited and is not necessarily indicative of future results.
SImmetry+ is a minimally invasive system for fusing the sacroiliac joint, which connects the pelvis and lower spine. Tenon added two implant sizes following input from Alpha users and newly trained surgeons. The company plans to expand instrument set inventory as needed to support anticipated demand and expects additional product launches in the coming quarters. Tenon acquired SImmetry+ in August 2025; its portfolio also includes the Catamaran SI Joint Fusion System.
Tenon Medical (TNON) closed a warrant inducement agreement with an institutional investor that generated gross cash proceeds of approximately $2,872,338 on September 14, 2026.
The investor exercised outstanding warrants to purchase an aggregate of 572,179 shares of common stock (Existing Warrants) and, as consideration for this immediate exercise, received new unregistered warrants to buy up to 858,269 shares of common stock, equal to 150% of the shares issued on exercise of the Existing Warrants. The New Warrants have an exercise price of $5.02 per share, are immediately exercisable, and expire five years from issuance. Gross proceeds exclude any funds from future exercises of the New Warrants and will be reduced by financial advisor fees and other expenses. WallachBeth Capital acted as financial advisor, and Tenon plans to file a resale registration statement with the SEC for the New Warrant shares.
Tenon Medical (TNON) closed a warrant inducement transaction on September 14, 2026 with an institutional investor, generating gross cash proceeds of approximately $2.87 million.
The investor exercised outstanding warrants to purchase an aggregate of 572,179 common shares. In return, the investor received new unregistered warrants to buy up to 858,269 additional shares, equal to 150% of the shares issued upon the exercise of the existing warrants, with an exercise price of $5.02 per share. The New Warrants are immediately exercisable and expire five years from issuance. Gross proceeds of $2,872,338.58 exclude any future proceeds from New Warrant exercises and are stated before advisor fees and other expenses. WallachBeth Capital acted as financial advisor. The company plans to file a resale registration statement for the New Warrant shares.
Tenon Medical (TNON) entered into warrant exercise agreements with an institutional investor to immediately exercise outstanding warrants for 572,179 common shares, generating expected gross cash proceeds of approximately $2,872,338.58.
In return, the investor will receive in a private placement new unregistered warrants to purchase up to 858,269 common shares, equal to 150% of the shares issued on exercise of the existing warrants, at an exercise price of $5.02 per share. The new warrants are immediately exercisable and will expire five years from issuance. Closing is expected on or about September 14, 2026, subject to customary conditions. Tenon expects gross proceeds of $2,872,338.58 before advisor fees and expenses, excluding any additional proceeds from future exercises of the new warrants.
Tenon Medical (TNON) entered warrant exercise agreements raising about $2.87 million in gross proceeds on September 11, 2026.
An institutional investor agreed to immediately exercise outstanding warrants for 572,179 common shares, providing gross cash proceeds of $2,872,338.58. In return, the investor will receive in a private placement new unregistered warrants to purchase up to 858,269 common shares, equal to 150% of the shares issued upon exercise of the existing warrants, with an exercise price of $5.02 per share. The New Warrants are exercisable immediately and expire five years from issuance. Closing is expected on or about September 14, 2026, subject to customary conditions, with WallachBeth Capital acting as financial advisor. Tenon plans to file a resale registration statement for the shares underlying the New Warrants.
Tenon Medical (TNON) has fully repaid its outstanding original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million, ahead of their September 11, 2026 maturity date.
The Notes were issued on March 11, 2026. The company states that the early repayment strengthens its balance sheet and removes the potential for the Notes to convert into common stock at a discount to market prices. Management describes the move as reducing potential shareholder dilution and preserving greater financial flexibility to invest in commercialization of its sacroiliac joint (SI Joint) fusion systems and broader growth initiatives.
Tenon Medical (NASDAQ: TNON) closed a previously announced private placement with an institutional investor, arranged by WallachBeth Capital, raising an estimated $3.0 million in gross proceeds. Tenon sold 597,610 common shares (or pre-funded warrants) plus warrants to purchase up to 1,058,517 common shares.
The combined effective price was $5.02 per share and accompanying warrants, or $5.019 per pre-funded warrant and accompanying warrants. Warrants are immediately exercisable at $5.02 per share and expire five years from issuance. The offering was conducted as an unregistered private placement under Section 4(a)(2) and Regulation D. WallachBeth’s release notes the first paragraph has been corrected for accuracy.
Tenon Medical (NASDAQ: TNON) closed a previously announced private placement with an institutional investor, selling 597,610 shares of common stock (or pre-funded warrants in lieu thereof) plus warrants to purchase up to 1,058,517 shares of common stock.
The combined effective offering price is $5.02 per share and accompanying warrants, or $5.019 per pre-funded warrant and accompanying warrants. According to Tenon Medical, gross proceeds are estimated at about $3.0 million before fees and expenses. The investor warrants are immediately exercisable at $5.02 per share for five years. WallachBeth Capital acted as exclusive placement agent, and Tenon agreed to provide customary registration rights for the shares and warrant shares.
Tenon Medical (Nasdaq:TNON) has closed a previously announced private placement with an institutional investor, issuing 597,610 shares of common stock (or pre-funded warrants in lieu thereof) plus warrants to purchase up to 1,058,517 shares of common stock. The combined effective offering price is $5.02 per share and accompanying warrants, and $5.019 per pre-funded warrant and accompanying warrants.
The pre-funded warrants have a $0.001 exercise price per share, while the warrants have a $5.02 exercise price, are immediately exercisable, and expire five years from issuance. According to Tenon Medical, gross proceeds are estimated at approximately $3.0 million before fees and expenses, and the company has granted customary registration rights for the shares and underlying warrant shares. WallachBeth Capital acted as exclusive placement agent.
Tenon Medical (Nasdaq: TNON) entered into a securities purchase agreement on August 27, 2026, with an institutional investor to sell 597,610 shares of common stock (or pre-funded warrants) plus warrants for up to 1,058,517 shares in a private placement priced at $5.02 per share-and-warrant unit ($5.019 for each pre-funded warrant unit). Pre-funded warrants have a $0.001 exercise price; accompanying warrants are exercisable at $5.02, immediately exercisable, and expiring five years after issuance.
According to the company, gross proceeds are expected to be about $3.0 million before fees, with closing targeted on or about August 31, 2026, subject to customary conditions. WallachBeth Capital is acting as sole placement agent, and Tenon has agreed to provide customary registration rights.